Dishman Carbogen Amcis Limited
₹145.15-₹3.90 (-2.6%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹4,132 Cr
- EV / EBITDA
- 67.5x
- Revenue
- ₹400 Cr
- Net margin
- -23.2%
- ROCE
- 0.2%
Price chart
Technical chartScreen technicals →-50.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -7.5%
- 3M
- -21.7%
- 6M
- -20.9%
- 1Y
- -50.5%
- 5Y
- -31.6%
52-week range
Day change -₹3.90 (-2.6%) from ₹149 to ₹145 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in DCAL, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Revenue grew 22.3% YoY
Concerns1
- Low interest coverage ratio of 0.1x
Rule-based from financial data. Not advice.
About the company
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments.
Read moreShow less
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wash, sanitisers, and antiseptics. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
- Sector
- Healthcare
- Shares outstanding
- 15.7 Cr shares
- ISIN
- INE385W01011
- BSE code
- 540701
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹4,132 Cr
- P/B
- 1.0x
- EV / EBITDA
- 67.5x
- EV / Sales
- 13.8x
- P/S
- 12.6x
- 52-week high
- ₹297.15
- 52-week low
- ₹130.00
Profitability
- Operating margin
- 2.1%
- Net margin
- -23.2%
- EBITDA margin
- 20.5%
- ROE
- -1.9%
- ROCE
- 0.2%
- ROA
- -1.5%
- Dividend payout
- 0.0%
- Tax rate
- -26.0%
- Other income, % of PBT
- -58.3%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹400 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 22.3%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -10.9%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹67.0 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 15.5%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -86.8%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹24.0 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -145.3%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹64.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -2.0%
Solvency and efficiency
- Current ratio
- 7.35
- Debt / Equity
- 0.13
- Debt / Assets
- 0.11
- Debt / EBITDA
- 8.00
- Interest coverage
- 0.10
- Financial leverage
- 1.25
- CFO / Net profit
- -0.32
- Cash / Market cap
- 17.9%
- Cash per share
- ₹47.04
- Asset turnover
- 0.06
- Fixed asset turnover
- 0.23
- Capital intensity
- 4.33
- Debtor days
- 205 days
- Inventory turnover
- 0.68
- Cash conversion cycle
- 374 days
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Sales | ₹400 Cr |
| Expenses | ₹328 Cr |
| Operating profit | ₹72 Cr |
| Other income | ₹33 Cr |
| Interest | ₹70 Cr |
| Depreciation | ₹65 Cr |
| Profit before tax | -₹31 Cr |
| Tax and other | -₹21 Cr |
| Net profit | -₹10 Cr |
Revenue and net profit
Revenue grew 22.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹200 Cr | -₹233 Cr |
| FY2022 | ₹307 Cr | -₹32 Cr |
| FY2023 | ₹403 Cr | -₹59 Cr |
| FY2024 | ₹327 Cr | -₹76 Cr |
| FY2025 | ₹400 Cr | -₹10 Cr |
Cash flows
FY2025: ₹56.0 Cr from operations, -₹24.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | -₹2 Cr | ₹60 Cr |
| FY2022 | ₹227 Cr | ₹54 Cr |
| FY2023 | -₹53 Cr | -₹12 Cr |
| FY2024 | ₹24 Cr | ₹121 Cr |
| FY2025 | ₹56 Cr | -₹24 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹400 Cr+22.3%1Y
- Net profit
- -₹10 Cr
- Cash from operations
- ₹56 Cr
- Free cash flow
- -₹24 Cr-119.8%1Y
- Revenue CAGR, 5Y
- -10.9%
- EBITDA CAGR, 5Y
- -22.7%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹400 Cr | ₹72 Cr | — | -₹10 Cr | ₹56 Cr | -₹24 Cr | -0.2% | +22.3% | -86.8% |
Monthly returns
Month-by-month returns of DCAL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹5,122 Cr |
| Equity capital | ₹31 Cr |
| Reserves | ₹3,999 Cr |
| Borrowings | ₹686 Cr |
| Other liabilities | ₹405 Cr |
| Assets | ₹5,122 Cr |
| Fixed assets | ₹1,401 Cr |
| Capital work in progress | ₹41 Cr |
| Investments | ₹2,841 Cr |
| Other assets | ₹840 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
DCAL has no positive P/E; the peer median is 52.6x.
Not shown (no positive earnings and no EV / Sales): Dishman Carbogen Amcis Limited, Sun Pharma Advanced Research Company Ltd.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Dishman Carbogen Amcis LimitedDCALthis company | ₹4,132 Cr | — | 1.0x | -1.9% | 67.5x |
| Sun Pharma Advanced Research Company Ltd.SPARC | ₹4,415 Cr | — | -12.6x | -312.9% | -11.7x |
| Artemis Medicare Services LimitedARTEMISMED | ₹4,059 Cr | 42.6x | 4.0x | 10.8% | 32.0x |
| Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,008 Cr | 83.0x | 15.1x | 29.4% | 48.1x |
| INNOVA CAPTAB LIMITEDINNOVACAP | ₹3,945 Cr | 51.8x | 4.6x | 9.4% | 34.2x |
| RPG Life Sciences LimitedRPGLIFE | ₹3,806 Cr | 34.2x | 6.9x | 23.5% | 27.7x |
| SENORES PHARMACEUTICALS LIMITEDSENORES | ₹3,750 Cr | 307.0x | 5.2x | 0.6% | 545.5x |
| Indraprastha Medical Corporation LtINDRAMEDCO | ₹3,742 Cr | 21.4x | 5.7x | 25.9% | 17.5x |
| Orchid Pharma LimitedORCHPHARMA | ₹3,739 Cr | 51.8x | 2.8x | — | — |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
DCAL since 1 January, against earlier years.
Historical volatility
DCAL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | -26.0% |
| FY2022 | 13.0% |
| FY2023 | 2.0% |
| FY2024 | 2.0% |
| FY2025 | 18.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹400 Cr |
| Costs | |
| Interest | ₹70 Cr |
| Expenses | ₹328 Cr |
| Operating profitOperating Profit | ₹72 Cr |
| Other income and charges | |
| Profit before tax | -₹31 Cr |
| Tax | |
| Net profitNet Profit | -₹10 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹5,122 Cr |
| Equity capitalEquity Capital | ₹31 Cr |
| Reserves | ₹3,999 Cr |
| Borrowings | ₹686 Cr |
| Other liabilitiesOther Liabilities | ₹405 Cr |
| AssetsTotal Assets | ₹5,122 Cr |
| Fixed assetsFixed Assets | ₹1,401 Cr |
| Capital work in progressCWIP | ₹41 Cr |
| Investments | ₹2,841 Cr |
| Other assetsOther Assets | ₹840 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹56 Cr |
| Investing cash flowCash from Investing Activity | -₹80 Cr |
| Financing cash flowCash from Financing Activity | ₹88 Cr |
| Change in cashNet Cash Flow | ₹64 Cr |
Learn while you research
Academy chapters picked for Dishman Carbogen Amcis Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Growth Investing22% revenue growth is in the top tier, learn how to value growth.7 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read